CMMB
Companies
NASDAQ
Chemomab Therapeutics Ltd.
Health Care
$1.23
-$0.59 (-32.60%)
Price Chart
Overview
About CMMB
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Market Cap
$14.5M
Volume
290.1K
Avg. Volume
184.5K
P/E Ratio
-25.5
Dividend Yield
0.00%
Employees
20.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.24
Moderate Correlation
Volatility
High (0.94)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CMMB shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$14.5M
Volume290.1K
P/E Ratio-25.50
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 3, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025